135 related articles for article (PubMed ID: 6761868)
1. The anticancer spectrum of ifosfamide.
Hunter HL; Harrison EF
Semin Oncol; 1982 Dec; 9(4 Suppl 1):96-100. PubMed ID: 6761868
[No Abstract] [Full Text] [Related]
2. Ifosfamide--pharmacology, safety and therapeutic potential.
Brade WP; Herdrich K; Varini M
Cancer Treat Rev; 1985 Mar; 12(1):1-47. PubMed ID: 3896483
[No Abstract] [Full Text] [Related]
3. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
Schnitker J; Brock N; Burkert H; Fichtner E
Arzneimittelforschung; 1976; 26(10):1783-92. PubMed ID: 798586
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide.
Zalupski M; Baker LH
J Natl Cancer Inst; 1988 Jun; 80(8):556-66. PubMed ID: 3286879
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide: European perspective.
Burkert H
Semin Oncol; 1982 Dec; 9(4 Suppl 1):28-35. PubMed ID: 6761866
[No Abstract] [Full Text] [Related]
6. [Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
Hoefer H; Scheef W; Titscher R; Kokron O
Osterr Z Onkol; 1974; (1):3-7. PubMed ID: 4619650
[No Abstract] [Full Text] [Related]
7. Ifosfamide vs cyclophosphamide in cancer therapy.
Weiss RB
Oncology (Williston Park); 1991 May; 5(5):67-76; discussion 76-82, 84-6. PubMed ID: 1653004
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide and Mesna in advanced malignancies.
Li GC; Brock N; Li JQ; Guan ZZ; He YJ
Chin Med J (Engl); 1988 Mar; 101(3):213-20. PubMed ID: 3136996
[No Abstract] [Full Text] [Related]
9. [Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
Hartwich G; Neidhardt B; Lutz H
Med Klin; 1978 Sep; 73(36):1247-52. PubMed ID: 692477
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experience with the cytostatic drug ifosfamide].
Ritter S; Schröder HJ
Med Welt; 1977 Sep; 28(35):1395-1400. PubMed ID: 70737
[No Abstract] [Full Text] [Related]
11. Ifosfamide treatment of advanced ovarian cancer.
Yazigi R; Wild R; Madrid J; Arraztoa J
Obstet Gynecol; 1984 Feb; 63(2):163-6. PubMed ID: 6694809
[TBL] [Abstract][Full Text] [Related]
12. Use and safety of high-dose ifosfamide.
Holoye PY; Anderson T; Duelge J; Hansen RM; Ritch PS
Semin Oncol; 1982 Dec; 9(4 Suppl 1):78-86. PubMed ID: 6298946
[No Abstract] [Full Text] [Related]
13. The value of ifosfamide in the polychemotherapy of metastasized testicular cancer pretreated with chemotherapy.
Clemm C; Hartenstein R; Wilmanns W
Arzneimittelforschung; 1982; 32(12):1557-60. PubMed ID: 6891596
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of ifosfamide in one-agent chemotherapy of malignant testicular tumors].
Madej G; Porwit-Ksiazek A; Siedlecki P; Zborzil J
Pol Tyg Lek; 1982 Jul; 37(24-25):717-9. PubMed ID: 6294642
[No Abstract] [Full Text] [Related]
15. Ifosfamide in the treatment of bronchogenic carcinoma. A preliminary trial.
Gandola L; Pozzi E; Tansini G
G Ital Chemioter; 1978; 25(1):41-4. PubMed ID: 376387
[No Abstract] [Full Text] [Related]
16. [Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)].
Teufel G; Pfleiderer A
Geburtshilfe Frauenheilkd; 1976 Mar; 36(3):274-9. PubMed ID: 1261795
[TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy.
Retsas S
Cancer Treat Rev; 1983 Sep; 10 Suppl A():151-7. PubMed ID: 6627241
[No Abstract] [Full Text] [Related]
18. Further experience with isophosphamide.
Falkson G; Falkson HC
Cancer Treat Rep; 1976 Jul; 60(7):955-7. PubMed ID: 1009528
[No Abstract] [Full Text] [Related]
19. [Clinical evaluation of Iphosphamide in phracological treatment of neoplasms].
Madej G; Zelechowska JA
Pol Tyg Lek; 1975 Jun; 30(22):955-7. PubMed ID: 1135071
[No Abstract] [Full Text] [Related]
20. Ifosfamide: chemotherapy with new promise and new problems for the urologist.
Watson RA
Urology; 1984 Nov; 24(5):465-8. PubMed ID: 6495457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
